Table 7 Analysis of the factors influencing the renal composite outcome in different risk levels

Demographics

 Age

1.02

0.0879

1.01

0.355

1.03

< 0.0001

 Gender

0.70

0.1881

0.90

0.6994

1.17

0.3939

 BMI

0.97

0.3506

0.94

0.1197

0.91

0.0002

 SBP

1.02

0.0006

1.01

0.1391

1.01

0.0423

 DBP

1.04

< 0.0001

1.00

0.8466

1.01

0.3237

Comorbidities

 Diabetes mellitus

1.72

0.2481

0.49

0.3275

1.91

0.035

 Hypertension

1.36

0.2769

0.64

0.0837

1.35

0.0857

Clinical symptom (%)

 Nephrotic syndrome*

/

/

0.72

0.1855

0.93

0.7776

Laboratory measurements

 Alb

0.92

< 0.0001

0.97

0.1468

0.98

0.2994

 Total cholesterol

1.19

0.0025

1.13

0.0302

1.04

0.2685

 eGFR

0.99

0.2139

0.99

0.1096

0.99

0.0162

 Proteinuria

1.00

0.0011

1.00

0.8112

1.00

0.6837

 PLA2R Ab

1.00

0.4955

1.00

0.0059

1.00

0.2181

Comedication

 RASi

0.79

0.4927

1.66

0.1828

1.53

0.0455

 Other hypotensive drugs

4.85

< 0.0001

1.36

0.2285

1.90

0.0004

 Antiplatelets drug

1.21

0.4663

0.63

0.0673

0.54

0.0006

 Urate-lowering drugs

1.09

0.8492

0.79

0.5755

0.55

0.1193

 Lipid regulating agents

1.14

0.7168

0.73

0.293

0.93

0.7776

 Calcium supplements

1.70

0.0452

1.05

0.8472

1.11

0.569

 Stomach protectants

1.53

0.1275

0.34

0.0005

1.06

0.7466

 SGLT2i

0.76

0.7904

0.00

0.9967

0.00

0.9932

Immunosuppressive therapy

1.29

0.3536

0.50

0.0087

0.64

0.0116